Ionis Pharmaceuticals, Inc.
IONSNext catalyst
Donidalorsen
Hereditary Angioedema
Get an email about IONS's next catalysts
Track Ionis Pharmaceuticals (IONS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 9 more upcoming events in our data (earnings, Phase 1 readout, Phase 3 readout and more).See the timeline
10 upcoming, 1 past
IONS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.22 | FQ end Sep/2026 | Call: tbd
Donidalorsen Phase 3 Est. Readout
Primary completion for Donidalorsen trial (NCT05392114) in Hereditary Angioedema
SourcePhase 1
Ionis Pharmaceuticals has delayed the primary completion of its Phase 1/2a prion disease trial to February 2027. Arvinas is developing a Parkinson's disease biomarker candidate, with additional updates from Eledon, Sobi, Ovid, and CytomX also mentioned.
SourceOlezarsen Phase 3 Est. Readout
Primary completion for Olezarsen trial (NCT05681351) in Severe Hypertriglyceridemia
SourceION717 Phase 2 Est. Readout
Estimated primary completion for ION717 trial (NCT06153966) in Prion Disease. Topline data typically follows completion by weeks to months.
SourceOlezarsen Phase 3 Est. Readout
Primary completion for Olezarsen trial (NCT05185843) in Familial Chylomicronemia Syndrome
Sourceobudanersen Phase 3 Est. Readout
Estimated primary completion for obudanersen trial (NCT06914609) in Angelman Syndrome. Topline data typically follows completion by weeks to months.
SourceION582 Phase 3 Est. Readout
Primary completion for ION582 trial (NCT06914609) in Angelman Syndrome
SourceHow IONS's past catalysts played out
Market Overview
Stock performance and key metrics
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
WebsiteAlicaforsen
Ulcerative Colitis
ISIS 3521
Lung Cancer
obudanersen
Angelman Syndrome
mipomersen sodium
Lipid Metabolism, Inborn Errors
ION582
Angelman Syndrome
ION363
Amyotrophic Lateral Sclerosis
zilganersen
Alexander Disease
Inotersen
FAP
Mipomersen
Hypercholesterolemia
Eplontersen
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Tofersen
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Donidalorsen
Hereditary Angioedema
Volanesorsen
Familial Chylomicronemia Syndrome
Olezarsen
Familial Chylomicronemia Syndrome
ISIS apoC-III Rx
Hypertriglyceridemia
ION-682884
Healthy Volunteers
ISIS 14803
Hepatitis C, Chronic
ISIS-GCGRRx- Dose Level 1
Type 2 Diabetes
ISIS-FGFR4RX
Obesity
ISIS CRP Rx
Paroxysmal Atrial Fibrillation
IONIS DGAT2Rx
Hepatic Steatosis
sapablursen
Phlebotomy Dependent Polycythemia Vera
IONIS-FB-LRx
Macular Degeneration
IONIS-GHR-LRx
Acromegaly
IONIS-STAT3Rx
Advanced Cancers
IONIS-AGT-LRx
Chronic Heart Failure With Reduced Ejection Fraction
IONIS GHR-LRx
Acromegaly
GHR-LRX
Acromegaly
ISIS-FXIRx Dose #2
Venous Thromboembolism
ION440
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
ISIS-GCGRRx
Type 2 Diabetes
ISIS-GCGRRx - Dose Level 1
Type 2 Diabetes Mellitus
AKCEA-ANGPTL3-LRx
Familial Chylomicronemia Syndrome
ISIS 301012
Hypercholesterolemia, Familial
ISIS 681257
Elevated Lipoprotein(a)
ISIS 2503
Pancreatic Cancer
ION337
Dravet Syndrome
ISIS 678354
Hypertriglyceridemia
ISIS 14803, peginterferon alfa, ribavirin
Hepatitis C, Chronic
ISIS 721744
Covid19
ION775
Hypertriglyceridemia
Somatostatin Receptor Ligand (SRL)
Acromegaly
ISIS-FXIRx Dose #3
Venous Thromboembolism
IONIS-PKKRx (ISIS 546254)
Chronic Migraine
ISIS-GCGRRx- Dose Level 2
Type 2 Diabetes
daily OAD (metformin and/or sulfonylurea)
Type 2 Diabetes Mellitus
ISIS 703802
NAFLD
ISIS 443139
Huntington's Disease
ISIS-GCGRRx - Dose Level 2
Type 2 Diabetes Mellitus
ISIS-APO(a)Rx
Elevated Lipoprotein(a)
ION224
Steatohepatitis, Nonalcoholic
ISIS 113715
Type 2 Diabetes Mellitus
ISIS-GCCRRx
Type 2 Diabetes Mellitus
ISIS EIF4E Rx
Castrate-Resistant Prostate Cancer
ISIS 757456
Mild Hypertension
ISIS 416858
End-stage Renal Disease (ESRD)
ION717
Prion Disease
ISIS-PTP1BRx
Type 2 Diabetes Mellitus
ION904
Hypertension
ISIS 104838
Rheumatoid Arthritis
IONIS-DMPKRx
Myotonic Dystrophy Type 1
Fomivirsen sodium
Cytomegalovirus Retinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Alicaforsen | Phase 3 | Ulcerative Colitis | - | - |
ISIS 3521 | Phase 3 | Lung Cancer | - | - |
obudanersen | Phase 3 | Angelman Syndrome | - | - |
mipomersen sodium | Phase 3 | Lipid Metabolism, Inborn Errors | - | - |
ION582 | Phase 3 | Angelman Syndrome | - | - |
ION363 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
zilganersen | Phase 3 | Alexander Disease | - | Patent 2041 |
Inotersen | Phase 3 | FAP | - | Patent 2031 |
Mipomersen | Phase 3 | Hypercholesterolemia | - | - |
Eplontersen | Phase 3 | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | - | Patent 2034 |
Tofersen | Phase 3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | - | - |
Donidalorsen | Phase 3 | Hereditary Angioedema | - | - |
Volanesorsen | Phase 3 | Familial Chylomicronemia Syndrome | - | - |
Olezarsen | Phase 3 | Familial Chylomicronemia Syndrome | - | Patent 2034 |
ISIS apoC-III Rx | Phase 2 | Hypertriglyceridemia | - | - |
ION-682884 | Phase 2 | Healthy Volunteers | - | - |
ISIS 14803 | Phase 2 | Hepatitis C, Chronic | - | - |
ISIS-GCGRRx- Dose Level 1 | Phase 2 | Type 2 Diabetes | - | - |
ISIS-FGFR4RX | Phase 2 | Obesity | - | - |
ISIS CRP Rx | Phase 2 | Paroxysmal Atrial Fibrillation | - | - |
IONIS DGAT2Rx | Phase 2 | Hepatic Steatosis | - | - |
sapablursen | Phase 2 | Phlebotomy Dependent Polycythemia Vera | - | - |
IONIS-FB-LRx | Phase 2 | Macular Degeneration | - | - |
IONIS-GHR-LRx | Phase 2 | Acromegaly | - | - |
IONIS-STAT3Rx | Phase 2 | Advanced Cancers | - | - |
IONIS-AGT-LRx | Phase 2 | Chronic Heart Failure With Reduced Ejection Fraction | - | - |
IONIS GHR-LRx | Phase 2 | Acromegaly | - | - |
GHR-LRX | Phase 2 | Acromegaly | - | - |
ISIS-FXIRx Dose #2 | Phase 2 | Venous Thromboembolism | - | - |
ION440 | Phase 2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | - | - |
ISIS-GCGRRx | Phase 2 | Type 2 Diabetes | - | - |
ISIS-GCGRRx - Dose Level 1 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
AKCEA-ANGPTL3-LRx | Phase 2 | Familial Chylomicronemia Syndrome | - | - |
ISIS 301012 | Phase 2 | Hypercholesterolemia, Familial | - | - |
ISIS 681257 | Phase 2 | Elevated Lipoprotein(a) | - | - |
ISIS 2503 | Phase 2 | Pancreatic Cancer | - | - |
ION337 | Phase 2 | Dravet Syndrome | - | - |
ISIS 678354 | Phase 2 | Hypertriglyceridemia | - | - |
ISIS 14803, peginterferon alfa, ribavirin | Phase 2 | Hepatitis C, Chronic | - | - |
ISIS 721744 | Phase 2 | Covid19 | - | - |
ION775 | Phase 2 | Hypertriglyceridemia | - | - |
Somatostatin Receptor Ligand (SRL) | Phase 2 | Acromegaly | - | - |
ISIS-FXIRx Dose #3 | Phase 2 | Venous Thromboembolism | - | - |
IONIS-PKKRx (ISIS 546254) | Phase 2 | Chronic Migraine | - | - |
ISIS-GCGRRx- Dose Level 2 | Phase 2 | Type 2 Diabetes | - | - |
daily OAD (metformin and/or sulfonylurea) | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS 703802 | Phase 2 | NAFLD | - | - |
ISIS 443139 | Phase 2 | Huntington's Disease | - | - |
ISIS-GCGRRx - Dose Level 2 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS-APO(a)Rx | Phase 2 | Elevated Lipoprotein(a) | - | - |
ION224 | Phase 2 | Steatohepatitis, Nonalcoholic | - | - |
ISIS 113715 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS-GCCRRx | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ISIS EIF4E Rx | Phase 2 | Castrate-Resistant Prostate Cancer | - | - |
ISIS 757456 | Phase 2 | Mild Hypertension | - | - |
ISIS 416858 | Phase 2 | End-stage Renal Disease (ESRD) | - | - |
ION717 | Phase 2 | Prion Disease | - | - |
ISIS-PTP1BRx | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ION904 | Phase 2 | Hypertension | - | - |
ISIS 104838 | Phase 2 | Rheumatoid Arthritis | - | - |
IONIS-DMPKRx | Phase 2 | Myotonic Dystrophy Type 1 | - | - |
Fomivirsen sodium | Phase 2 | Cytomegalovirus Retinitis | - |
Type 2 Diabetes Mellitus
4 drugs in this indication
Acromegaly
2 drugs in this indication
Familial Chylomicronemia Syndrome
2 drugs in this indication
Hypertension
2 drugs in this indication
Huntington's Disease
2 drugs in this indication
Alexander Disease
2 drugs in this indication
Rheumatoid Arthritis
2 drugs in this indication
Steatohepatitis, Nonalcoholic
1 drug in this indication
Angelman Syndrome
1 drug in this indication
Obesity
1 drug in this indication
Elevated Lipoprotein(a)
1 drug in this indication
Mild Hypertension
1 drug in this indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
1 drug in this indication
Amyotrophic Lateral Sclerosis
1 drug in this indication
FAP
1 drug in this indication
Paroxysmal Atrial Fibrillation
1 drug in this indication
Phlebotomy Dependent Polycythemia Vera
1 drug in this indication
Ulcerative Colitis
1 drug in this indication
Castrate-Resistant Prostate Cancer
1 drug in this indication
Hepatic Steatosis
1 drug in this indication
Macular Degeneration
1 drug in this indication
End-stage Renal Disease (ESRD)
1 drug in this indication
Type 2 Diabetes
1 drug in this indication
Hereditary Angioedema
1 drug in this indication
Advanced Cancers
1 drug in this indication
Hypertriglyceridemia
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Chronic Heart Failure With Reduced Ejection Fraction
1 drug in this indication
Cytomegalovirus Retinitis
1 drug in this indication
Healthy Volunteers
1 drug in this indication
Prion Disease
1 drug in this indication
Myotonic Dystrophy Type 1
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Ionis Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 62 drug candidates in Ionis Pharmaceuticals, Inc.'s (IONS) pipeline across Phase 3, Phase 2. Its lead program is Olezarsen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ionis Pharmaceuticals, Inc.'s next FDA catalyst?→
Ionis Pharmaceuticals, Inc.'s (IONS) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IONS biotech catalysts?→
Add IONS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ionis Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.